Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
About Apyx Medical Corporation
Apyx Medical Corporation (NASDAQ: APYX) is an advanced energy technology company specializing in the development, manufacturing, and marketing of innovative medical devices for the cosmetic and surgical markets worldwide. With a strong focus on leveraging proprietary technologies, Apyx delivers cutting-edge solutions that elevate surgical precision and aesthetic outcomes.
The company operates through two primary business segments: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment is centered around its patented Helium Plasma Platform Technology, which is marketed under the Renuvion brand name in the cosmetic surgery market and as J-Plasma in the hospital surgical market. These technologies enable surgeons to achieve unparalleled precision in cutting, coagulation, and ablation of soft tissue while minimizing unintended tissue trauma. The Renuvion system, in particular, empowers plastic surgeons, facial plastic surgeons, and cosmetic physicians to deliver controlled heat to tissue, enhancing patient outcomes in body contouring and other aesthetic procedures.
In addition to its proprietary technologies, Apyx's OEM segment designs, develops, and manufactures electrosurgical generators and related accessories for other medical device manufacturers. This segment leverages the company's decades of expertise in advanced waveforms, allowing it to establish strategic partnerships and diversify its revenue streams.
Industry Position and Market Impact
Apyx Medical Corporation operates at the intersection of the medical device and cosmetic surgery industries, addressing a growing demand for minimally invasive and precise surgical solutions. The company's Renuvion and J-Plasma technologies are supported by extensive clinical validation, with over 90 published clinical documents attesting to their efficacy and safety. This robust evidence base enhances the company's credibility and fosters trust among surgeons and patients alike.
By focusing on innovation and quality, Apyx distinguishes itself in a competitive landscape that includes other advanced energy technology providers. Its ability to address both cosmetic and surgical applications positions it uniquely within its market segments, catering to a diverse customer base that spans hospitals, surgery centers, and private practices.
Commitment to Innovation and Quality
As a company formerly known as Bovie Medical Corporation, Apyx has a legacy of expertise in energy-based medical technologies. Its ongoing commitment to research and development ensures that it remains at the forefront of surgical innovation. By integrating advanced technology with user-centric design, Apyx continues to enhance the capabilities of surgeons and improve patient outcomes.
Conclusion
Apyx Medical Corporation exemplifies the convergence of innovation, precision, and clinical excellence in the medical device industry. Through its proprietary Helium Plasma Platform Technology and strategic OEM partnerships, the company addresses critical needs in both surgical and cosmetic markets. With a focus on delivering transformative solutions and maintaining rigorous quality standards, Apyx is well-positioned to drive meaningful advancements in the field of energy-based medical devices.
Apyx Medical Corporation (NASDAQ: APYX) has launched the Apyx One Console, an advanced energy system now available to U.S. medical professionals. This multi-functional generator integrates Renuvion technology with monopolar and bipolar energy capabilities. Key features include adaptive touch screens, cloud connectivity, and a four-year warranty. Designed in collaboration with leading physicians, the Apyx One Console aims to enhance user experience and provides an upgrade option for existing customers. This product reinforces Apyx's commitment to innovation in the cosmetic surgery market.
Apyx Medical Corporation (NASDAQ:APYX) reported preliminary revenue results for Q4 and full year 2022, revealing a total revenue range of $12.1 to $12.5 million for Q4, a decline of 28% to 26% year-over-year. For the full year, revenue ranged from $44.0 to $44.4 million, declining by 9% to 8% year-over-year. The Advanced Energy segment showed significant declines of 33% to 30% in Q4 and 15% to 14% for the full year, while OEM revenue grew 12% in Q4 and 37% for the year. Despite challenges, the company plans for over 35% growth in 2023 driven by regulatory objectives.
Apyx Medical Corporation (NASDAQ: APYX) announces the launch of its inaugural direct-to-consumer campaign, #ThisIsMe, aimed at promoting its Renuvion technology for minimally invasive procedures. The campaign features national digital advertising and social media initiatives targeting consumers seeking aesthetic improvements. This campaign follows recent FDA clearances for Renuvion, specifically for treating loose skin on the chin and neck. The marketing efforts are designed to enhance brand awareness and highlight the technology's unique benefits, positioning Renuvion as a leader in cosmetic procedures.
Apyx Medical Corporation (NASDAQ:APYX) announced its participation in the Piper Sandler 34th Annual Healthcare Conference on November 30 at 11:00 a.m. ET, held at the Lotte New York Palace. Management will engage in a fireside chat, accessible via a live audio webcast on the Company's investor relations website.
Apyx Medical specializes in advanced energy technologies, notably its Helium Plasma Technology branded as Renuvion® for cosmetic and J-Plasma® for surgical markets, offering innovative solutions for tissue management.
Apyx Medical Corporation (NASDAQ: APYX) reported third-quarter 2022 results, revealing total revenue of $9.1 million, down 23% year-over-year. Advanced Energy revenue fell 31% to $7.1 million, while OEM revenue rose 34% to $2.0 million. The company recorded a net loss of $5.8 million, worsening from $4.2 million in Q3 2021. Due to ongoing disruptions from an FDA Safety Communication, Apyx revised its 2022 revenue guidance to a range of $44.8 million to $47.9 million, reflecting a potential decline of 8% to 1%. The management emphasized efforts to engage customers and secure new regulatory clearances.
Apyx Medical Corporation (NASDAQ:APYX) will release its third quarter financial results for fiscal year 2022 before the market opens on November 10th. A conference call, scheduled for 8:00 a.m. ET on the same day, will discuss the quarterly results and include a question and answer session. Interested participants can join via phone or listen to a live webcast through the company’s Investor Relations webpage. A replay of the call will be available for two weeks post-event.
Apyx Medical Corporation (NASDAQ: APYX) announced a new surgeon testimonial video featuring its Renuvion Helium Plasma Technology. Leading plastic surgeons, including Dr. Paul Nassif, attest to the device's effectiveness in achieving superior cosmetic results. Renuvion is FDA-cleared for improving lax skin on the neck and for specific dermatological procedures. Hundreds of physicians in the U.S. utilize this innovative technology in their practices, highlighting its safety and efficacy.
Apyx Medical Corporation (NASDAQ:APYX) has announced its participation in the Lake Street Best Ideas Growth Conference on September 14th at The Yale Club, New York, NY. Management will engage in one-on-one meetings, but there will not be a formal presentation. The company specializes in advanced energy technology, offering innovative helium plasma products such as Renuvion® for cosmetic surgery and J-Plasma® for hospital surgeries. These technologies provide controlled heating for optimal surgical results.
Apyx Medical Corporation (NASDAQ: APYX) reported a second quarter 2022 revenue of $10.3 million, an 8% decrease year-over-year. Advanced Energy revenues fell 16% to $8.4 million, while OEM revenues rose 55% to $1.9 million. The net loss increased to $5.4 million from $4.0 million in Q2 2021. The company adjusted its full-year revenue guidance to $51.0 million to $56.4 million, reflecting a 5% to 16% growth expectation. Key 510(k) clearances from the FDA for Renuvion products were achieved, expanding market opportunities.
Apyx Medical Corporation (NASDAQ:APYX) has unveiled its inaugural environmental, social, and governance (ESG) data through a newly released tear sheet. This document, compiled with third-party assistance, highlights the Company's ESG priorities and sets a baseline for future assessments. It includes data for the year ending December 31, 2021, focusing on environmental, social, and governance issues, including energy management, product safety, and Board diversity. CEO Charlie Goodwin emphasized the importance of these efforts to positively impact employees and stakeholders.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
What does Apyx Medical Corporation specialize in?
What are Apyx's primary product offerings?
How does Apyx generate revenue?
What markets does Apyx serve?
What differentiates Apyx from competitors?
What is the Renuvion system used for?
What is the J-Plasma system designed for?
What is Apyx's approach to innovation?
Does Apyx have strategic partnerships?
What is Apyx's legacy in the medical device industry?
